Fertility and Gonadal Function after First-Line Treatment with Nivolumab-AVD in Hodgkin Lymphoma Patients: An Analysis from the Phase II GHSG Nivahl Trial

被引：0

作者：

Broeckelmann, Paul J. ^{[1
]}

Buehnen, Ina ^{[1
]}

Herhaus, Peter ^{[2
]}

Meissner, Julia ^{[3
]}

Trautmann-Grill, Karolin ^{[4
]}

Mueller, Horst ^{[1
]}

Fuchs, Michael ^{[1
]}

von Tresckow, Bastian ^{[5
]}

Borchmann, Peter ^{[1
]}

Engert, Andreas ^{[1
]}

Behringer, Karolin ^{[1
]}

机构：

[1] Univ Hosp Cologne, Dept Internal Med, German Hodgkin Study Grp GHSG, Cologne, Germany

[2] Tech Univ Munich, Sch Med, Clin & Policlin Internal Med 3, Klinikum Rechts Isar, Munich, Germany

[3] Univ Hosp Heidelberg, Med 5, Heidelberg, Germany

[4] Univ Hosp Carl Gustav Carus, Med Clin 1, Dresden, Germany

[5] West German Canc Ctr Essen, Dept Hematol & Stem Cell Transplantat, Essen, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-189250

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Rituximab maintenance after R-CHOP in the first-line treatment of follicular lymphoma: A GOTEL phase II trial [J].

Rueda, A. ;

Provencio, M. ;

Abrio, M. ;

Gomez-Codina, J. ;

Llanos, M. ;

Delgado, J. ;

Rifa, J. ;

Sabin, P. ;

Velez de Mendizabal, E. ;

Baz, V. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)

[22] Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial [J].

Broeckelmann, Paul J. ;

Boell, Boris ;

Molin, Daniel ;

Schneider, Gundolf ;

Leppae, Sirpa ;

Meissner, Julia ;

Kamper, Peter ;

Hutchings, Martin ;

Christensen, Jacob Haaber ;

Schnetzke, Ulf ;

Fuchs, Michael ;

Eichenauer, Dennis A. ;

von Tresckow, Bastian ;

Kaul, Helen ;

Borchmann, Peter ;

Fossa, Alexander .

BLOOD, 2024, 144 :3055-3055

[23] Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer [J].

Luo, Hui-yan ;

Xu, Rui-hua ;

Wang, Feng ;

Qiu, Miao-zhen ;

Li, Yu-hong ;

Li, Fang-hua ;

Zhou, Zhi-wei ;

Chen, Xiao-qin .

CHEMOTHERAPY, 2010, 56 (02) :94-100

[24] Rituximab, Lenalidomide, and Bortezomib in the First-Line or Second-Line Treatment of Patients with Mantle Cell Lymphoma a Phase I/II Trial [J].

Flinn, Ian W. ;

Mainwaring, Mark ;

Peacock, Nancy ;

Shipley, Dianna ;

Arrowsmith, Edward ;

Savona, Michael R. ;

Hainsworth, John D. ;

Berdeja, Jesus G. .

BLOOD, 2012, 120 (21)

[25] PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup [J].

Fornecker, Luc-Matthieu ;

Lazarovici, Julien ;

Aurer, Igor ;

Casasnovas, Rene-Olivier ;

Gac, Anne-Claire ;

Bonnet, Christophe ;

Bouabdallah, Krimo ;

Perrot, Aurore ;

Specht, Lena ;

Touati, Mohamed ;

Eisenmann, Jean Claude ;

Borel, Cecile ;

Stamatoullas, Aspasia ;

Nicolas-Virelizier, Emmanuelle ;

Pascal, Laurent ;

Lugtenburg, Pieternella ;

Bellei, Monica ;

Traverse-Glehen, Alexandra ;

Copie, Christiane ;

Hutchings, Martin ;

Versari, Annibale ;

Meignan, Michel ;

Federico, Massimo ;

Andre, Marc .

BLOOD, 2017, 130

[26] Nivolumab in Combination with Dose Adjusted (DA) R-EPOCH for First-Line Treatment of Large B-Cell Lymphoma: Results from a Phase II Trial [J].

Bond, David A. ;

Huang, Ying ;

Reneau, John C. ;

Sawalha, Yazeed ;

Brammer, Jonathan E. ;

Voorhees, Timothy ;

Epperla, Narendranath ;

Sigmund, Audrey M. ;

Alinari, Lapo ;

Hanel, Walter ;

Gilmore, Anna ;

Fleming, Misty ;

Stamper, Kathleen ;

Baiocchi, Robert ;

Christian, Beth ;

Maddocks, Kami J. .

BLOOD, 2024, 144 :1719-1720

[27] ANALYSIS OF HODGKIN'S LYMPHOMA PATIENTS WITH INCOMPLETE METABOLIC RESPONSE AFTER FIRST-LINE SYSTEMIC THERAPY [J].

Liao, Donna ;

Aminilari, Mahmood ;

Tsao, May ;

Ahmed, Sameera ;

Ye, Xiang Y. ;

Prica, Anca ;

Metser, Ur ;

Singnurkar, Amit ;

Hodgson, David .

RADIOTHERAPY AND ONCOLOGY, 2023, 186 :S4-S4

[28] ANALYSIS OF HODGKIN'S LYMPHOMA PATIENTS WITH INCOMPLETE METABOLIC RESPONSE AFTER FIRST-LINE SYSTEMIC THERAPY [J].

不详 .

RADIOTHERAPY AND ONCOLOGY, 2023, 186 :S4-S4

[29] Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM) [J].

Vasudev, N. S. ;

Ainsworth, G. ;

Brown, S. ;

Pickering, L. ;

Waddell, T. S. ;

Fife, K. ;

Griffiths, R. ;

Sharma, A. ;

Katona, E. ;

Howard, H. ;

Velikova, G. ;

Maraveyas, A. ;

Brown, J. E. ;

Venugopal, B. ;

Patel, P. ;

Jain, A. ;

Symeonides, S. ;

Nathan, P. D. ;

Collinson, F. ;

Powles, T. B. .

ANNALS OF ONCOLOGY, 2021, 32 :S1304-S1305

[30] Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial [J].

Hou, Zhenyu ;

Zhu, Keyun ;

Yang, Xuejiao ;

Chen, Ping ;

Zhang, Wei ;

Cui, Yunlong ;

Zhu, Xiaolin ;

Song, Tianqiang ;

Li, Qiang ;

Li, Huikai ;

Zhang, Ti .

ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (17)

← 1 2 3 4 5 →